Endocrine最新文献

{"title":"Improving in-hospital diabetes awareness and transition of care by a digitalized diabetes management.","authors":"Lukas van Baal, Johanna Reinold, Dagmar Fuhrer","doi":"10.1007/s12020-025-04368-8","DOIUrl":"https://doi.org/10.1007/s12020-025-04368-8","url":null,"abstract":"<p><strong>Purpose: </strong>Diabetes as common comorbidity is associated with an impaired outcome for inpatients. Inadequate transition of dysglycemia specific information from hospital to outpatient setting may disrupt continuity of care and contribute to impaired patient outcome. We tested whether a digitalized diabetes management improves awareness of in-hospital health care professionals for diabetes as comorbidity.</p><p><strong>Methods: </strong>SmartDiabetesCare, a digitalized diabetes management, was carried out prospectively on five non-ICU wards as a quality improvement project (QiP SDC) including systematic screening for dysglycemia at admission, flagging of identified cases, continuous glucose monitoring and a proactive diabetes-team. Chance for correctly documented dysglycemia specific information in discharge letters written during QiP SDC in comparison to usual diabetes care (UDC) was calculated and performance was assessed to evaluate the impact of QiP SDC on quality of diabetes-specific transition.</p><p><strong>Results: </strong>Discharge letters of 1141 cases were included in the analysis. Comparing QiP SDC to UDC, the odds ratio for complete correct transition of diabetes-specific information was 2.80 (95%CI: 1.48-5.29) in QiP SDC vs UDC. Accordingly, the performance score was significantly higher in QiP SDC (1.79 vs. 1.23, p < 0.01). If only patients with newly diagnosed dysglycemia were analyzed, OR for correct documentation increased to 9.22 (95%CI: 4.01-18.80) and performance score remained significantly higher in QiP SDC, but decreased compared to the overall population (0.60 vs. 0.16, p < 0.01).</p><p><strong>Conclusions: </strong>A digitalized diabetes management may raise awareness for diabetes in in-hospital health care professionals and improve quality of diabetes data transition potentially increasing the chance for continuity of care.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144734890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using machine learning to predict remission after surgery for pituitary adenoma: a systematic review and meta-analysis.","authors":"Ibrahim Mohammadzadeh, Bardia Hajikarimloo, Behnaz Niroomand, Pooya Eini, Mohammad Amin Habibi, Ali Mortezaei, Mohammad Hassan Bagheri, Ahmet Günkan, Daniel M Aaronson, Vratko Himic, Ricardo J Komotar","doi":"10.1007/s12020-025-04351-3","DOIUrl":"https://doi.org/10.1007/s12020-025-04351-3","url":null,"abstract":"<p><strong>Purpose: </strong>Postoperative remission in pituitary adenoma (PA) patients significantly affects treatment outcomes and quality of life. Accurate prediction of remission is crucial for neurosurgeons and oncologists as it aids in personalizing treatment plans, optimizing follow-up care, and preventing unnecessary interventions. Unlike diagnostic classification, this review specifically focuses on remission prediction as a distinct prognostic application of AI. This systematic review and meta-analysis aim to evaluate the performance of machine learning (ML) algorithms in predicting remission outcomes in PA patients.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, Scopus, Embase, Web of Science, and the google scholar was conducted to identify eligible studies until Dec 2024. Data on sensitivity, specificity, accuracy, precision, F1-score, and area under the curve (AUC) were extracted from the included studies.</p><p><strong>Results: </strong>Out of 1530 studies screened, 10 met our eligibility criteria involving ML approaches in patients with confirmed PA. ML algorithms, particularly artificial neural networks (ANN), offer promising performance for predicting remission outcomes in PA patients. Meta-analysis of 10 studies resulted in a pooled sensitivity of 0.84 (95% CI: 0.74-0.91), specificity of 0.84 (95% CI: 0.74-0.91), positive diagnostic likelihood ratio (DLR) of 0.19 (95% CI: 0.11-0.32), negative DLR of 15.26 (95% CI: 8.23-28.26), diagnostic odds ratio (DOR) of 28.25 (95% CI: 10.85-73.57), the diagnostic score was 3.34 (95% CI: 2.38-4.3) and an AUC of 0.91 (95% CI: 0.88-0.93).</p><p><strong>Conclusion: </strong>ML-based models demonstrate moderate to high diagnostic accuracy in predicting remission outcomes in PA patients. While these models show promise in enhancing clinical decision-making post-surgery, further prospective validation and larger studies are necessary before their routine clinical integration.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144709690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The oncogenic role of the circ_0003997/miR-370-3p/HMGA2 axis in papillary thyroid cancer.","authors":"Jing Ma, Juxiang Liu, Changhong Dong, Jun Wang, Limin Tian, Jinxing Quan","doi":"10.1007/s12020-025-04335-3","DOIUrl":"https://doi.org/10.1007/s12020-025-04335-3","url":null,"abstract":"<p><strong>Background: </strong>Papillary thyroid cancer (PTC) is the most common endocrine malignancy, demonstrating the most rapid incidence growth among solid tumors in the past decades. Notably, aggressive variants frequently manifest metastatic potential and therapeutic resistance, substantially compromising poor prognosis. Circular RNAs (circRNAs) have been recognized as pivotal regulators in diverse biological processes across multiple cancer types. However, the molecular mechanism underlying circ_0003997 (circCLMP) in PTC remains largely unexplored.</p><p><strong>Methods: </strong>The expression levels of circ_0003997, miR-370-3p, and HMGA2 were assessed using real-time quantitative polymerase chain reaction (RT-qPCR). The functions of circ_0003997 were evaluated through CCK-8 assays, wound healing assays, and Transwell assays in PTC cells. Western blotting was used to analyze the expression of key epithelial-mesenchymal transition (EMT) proteins. Tumor development in vivo was assessed using xenograft tumor models. The expression of Ki67 and HMGA2 in tumor tissues was evaluated by immunohistochemical (IHC) assay. Dual-luciferase reporter assays were performed to validate the interactions among circ_0003997, HMGA2, and miR-370-3p.</p><p><strong>Results: </strong>Circ_0003997 demonstrated significant upregulation in PTC tissues and cells. Functional validation experiments revealed that knockdown of circ_0003997 inhibited cell proliferation, migration, invasion, and EMT, while its overexpression promoted PTC progression. Mechanistically, circ_0003997 modulated HMGA2 expression by sponging miR-370-3p. Rescue experiments demonstrated that the oncogenic effects of circ_0003997 could be reversed by miR-370-3p. In vivo data showed that the decreased expression of circ_0003997 significantly suppressed tumor growth of PTC.</p><p><strong>Conclusions: </strong>We identified a novel biomarker panel consisting of the circ_0003997/miR-370-3p/HMGA2 axis, offering potential diagnostic and therapeutic avenues for PTC.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144734891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep disorders in patients with differentiated thyroid cancer: a case-control study.","authors":"Yuenan Zheng, Yang Shi, Qingshu Wu, Zhihong Wang, Hao Zhang, Lili Zhu, Liang He","doi":"10.1007/s12020-025-04358-w","DOIUrl":"https://doi.org/10.1007/s12020-025-04358-w","url":null,"abstract":"<p><strong>Objective: </strong>Thyroid cancer survivors are prone to sleep disorders. This study aims to compare the differences of sleep quality between patients with differentiated thyroid cancer (DTC) and healthy controls, as well as to investigate the risk factors for sleep disorders in DTC survivors.</p><p><strong>Methods: </strong>A case-control study was conducted. The Pittsburgh Sleep Quality Index (PSQI) was utilized to assess sleep quality, the Self-rating Anxiety Scale (SAS) to evaluate anxiety, and the Self-rating Depression Scale (SDS) to measure depression. Chi-square tests and Mann-Whitney tests were employed to identify differences between DTC patients and healthy controls. Univariate and multivariate logistic regression analyses were conducted to explore the independent risk factors for sleep disorders in DTC patients.</p><p><strong>Results: </strong>A total of 318 DTC patients and 72 healthy controls were included. Sleep disorders were prevalent, affecting 50.3% of DTC patients compared to 34.7% of healthy controls, with a significant difference noted (P = 0.017). Notable disparities were observed in sleep disturbances (P = 0.031) and daytime dysfunction (P = 0.019). Furthermore, employment status (P = 0.026), anxiety (P < 0.001), and depression (P = 0.001) were identified as independent predictors of sleep disorders in DTC patients.</p><p><strong>Conclusions: </strong>DTC patients are susceptible to sleep disorders, the prevalence was as high as 50.3%. Clinicians should be vigilant in identifying DTC patients who are unemployed or experiencing anxiety or depression, as these factors significantly influence sleep quality. Clinicians should offer these patients appropriate support and interventions, such as disease information support and multidisciplinary consultations, to enhance their overall well-being and quality of life.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144709689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediterranean diet, selenium and Graves' ophthalmopathy: a prospective, randomized, single-center study.","authors":"R Le Moli, T Piticchio, F Pallotti, G Geraci, A Tumminia, A Scuto, E Di Simone, V Paternò, M R Ruggeri, A Belfiore, F Frasca","doi":"10.1007/s12020-025-04360-2","DOIUrl":"https://doi.org/10.1007/s12020-025-04360-2","url":null,"abstract":"<p><strong>Purpose: </strong>Graves' ophthalmopathy (GO) is an autoimmune-inflammatory condition affecting about 25% of patients with Graves' disease (GD). Oxidative stress (OS) increases the production of inflammatory cytokines, the production of free radicals (ROS) and insulin resistance modulating IGF-1r/TSHr cross-talk in GO. Selenium is a component of selenoproteins and promotes the suppression of ROS production. We aim to evaluate the effects of the Mediterranean diet (MD) naturally enriched with selenium in patients with GD and active mild GO on thyroid function parameters, nutritional state, autoimmunity and the clinical course of GO.</p><p><strong>Methods: </strong>40 GD patients with untreated mild active GO and stable thyroid function were randomly assigned to the Mediterranean diet (MD) naturally enriched with selenium (MD group) or a free diet (FD group). The selenium content of the MD was increased by approximately 30% according to the reference levels of nutrient and energy intake for the Italian population (LARN 2014). The combined endocrinological-ophthalmological evaluation was carried - out at baseline and after 12 and 24 weeks from the beginning of the MD or FD.</p><p><strong>Results: </strong>The MD contained 178.1 ± 15.1 mcg of SE, and the diet was balanced with respect to the macronutrient composition. The Clinical Activity Score (CAS) improved significantly at visit 1 in the MD group compared to the FD group (p = 0.03). Hertel measurements and eyes motility were not different at visits 1 and 2 in either group of patients. Soft tissue involvement improved in the MD group compared to the FD group at visit 1 and 2 (p = 0.03 and 0.04). The absolute value (mm) of the eyelid aperture was significantly lower at visit 2 in the MD group than in the FD group (9.3 ± 0.6 vs. 10.5 ± 0.5, p = 0.01). The relative change in BMI was significantly lower in the MD group than in the FD group at visit 2 (2.5 [(-9.4) -10.1)] vs. 5.1 [(-0.4) -15)] kg, p = 0.04). TRABs values and thyroid function did not differ and decreased to a similar degree in both groups of patients during the observation period. No cases of GO exacerbation were observed in the two groups of patients.</p><p><strong>Conclusions: </strong>The MD is a versatile dietary style and should be a component of the dietary treatment plan in patients with GD and mild GO to reduce weight regain and the inflammation and insulin resistance, which in turn contribute to the autoimmune-inflammatory processes of GO.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144709688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-classical congenital adrenal hyperplasia: current insights into clinical implications, diagnosis and treatment.","authors":"Paola Loli, Sara Menotti, Luigi di Filippo, Andrea Giustina","doi":"10.1007/s12020-025-04341-5","DOIUrl":"https://doi.org/10.1007/s12020-025-04341-5","url":null,"abstract":"<p><strong>Background: </strong>Non-classical congenital adrenal hyperplasia (NCCAH) is a milder variant of 21-hydroxylase deficiency, an autosomal recessive disorder leading to impaired cortisol biosynthesis and compensatory adrenal androgen excess. Unlike the classical form, NCCAH typically presents later in life, often mimicking polycystic ovary syndrome (PCOS) in women and remaining largely asymptomatic in men.</p><p><strong>Methods: </strong>A literature search was conducted in MEDLINE (PubMed) in October 2024 using the term \"Non-Classical Congenital Adrenal Hyperplasia\" in combination with keywords related to sex differences, diagnosis, genetics, clinical presentation, metabolic risk, fertility, and treatment.</p><p><strong>Results: </strong>NCCAH prevalence varies significantly by ethnicity, ranging from 3.7% in Ashkenazi Jews to 0.1% in other Caucasian populations. In females, NCCAH often presents with symptoms of androgen excess, including hirsutism (60-80%), acne (30%), androgenic alopecia (2-8%), menstrual irregularities (56%), and, in rare cases, clitoromegaly (6-20%). Many affected women are misdiagnosed with PCOS, delaying appropriate management. In males, NCCAH remains largely asymptomatic and it is often diagnosed only through familial genetic screening or incidentally in fertility evaluations. A small percentage exhibit premature pubarche, tall stature, gynecomastia, or testicular adrenal rest tumors (TARTs). Regarding metabolic risks, conflicting evidence suggests that NCCAH may be associated with mild insulin resistance, obesity, and an increased cardiovascular risk, particularly in women. Bone mineral density (BMD) appears normal or even increased in NCCAH, possibly due to prolonged androgen exposure, though fracture risk remains uncertain. Treatment is generally reserved for symptomatic patients, with glucocorticoids, antiandrogens, and oral contraceptives being the main therapeutic approaches. While glucocorticoids reduce adrenal androgen excess, they pose risks of adrenal suppression and metabolic complications, making alternative therapies such as cyproterone acetate, spironolactone, and estrogen-progestin combinations preferable in many cases. Fertility outcomes in NCCAH are variable. Women may experience infertility due to androgen excess, dysovulation, and progesterone-mediated implantation issues. In males, fertility does not appear significantly impaired.</p><p><strong>Conclusions: </strong>NCCAH remains an underdiagnosed and poorly characterized condition, particularly in males. Further research is needed to establish standardized diagnostic thresholds, assess long-term metabolic risks, and optimize treatment strategies.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large language models: unlocking new potential in patient education for thyroid eye disease.","authors":"Yuwan Gao, Qi Xu, Ou Zhang, Hongliang Wang, Yunlong Wang, Jiale Wang, Xiaohui Chen","doi":"10.1007/s12020-025-04339-z","DOIUrl":"https://doi.org/10.1007/s12020-025-04339-z","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to evaluate the performance of three large language models (LLMs) in generating patient education materials (PEMs) for thyroid eye disease (TED), intending to improve patients' understanding and awareness of TED.</p><p><strong>Methods: </strong>We evaluated the performance of ChatGPT-4o, Claude 3.5, and Gemini 1.5 in generating PEMs for TED by designing different prompts. First, we produced TED patient educational brochures based on prompts A and B, respectively. Prompt B asked to make the content simple for sixth graders. Next, we designed two responses to frequently asked questions (FAQs) about TED: standard responses and simplified responses, where the simplified responses were optimized through specific prompts. All generated content was systematically evaluated based on dimensions such as quality, understandability, actionability, accuracy, and empathy. The readability of the content was analyzed using the online tool Readable.com (including FKGL: Flesch-Kincaid Grade Level and SMOG: Simple Measure of Gobbledygook).</p><p><strong>Results: </strong>Both prompt A and prompt B generated brochures that performed excellently in terms of quality (DISCERN ≥ 4), understandability (PEMAT Understandability ≥70%), accuracy (Score ≥4), and empathy (Score ≥4), with no significant differences between the two. However, both failed to meet the \"actionable\" standard (PEMAT Actionability <70%). Regarding readability, prompt B was easier to understand than prompt A, although the optimized version of prompt B still did not reach the ideal readability level. Additionally, a comparative analysis of FAQs about TED on Google using LLMs showed that, regardless of whether the response was standard or simplified, the LLM's performance outperformed Google, yielding results similar to those generated by the brochures.</p><p><strong>Conclusion: </strong>Overall, LLMs, as a powerful tool, demonstrate significant potential in generating PEMs for TED. They are capable of producing high-quality, understandable, accurate, and empathetic content, but there is still room for improvement in terms of readability.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global epidemiology of type 1 diabetes in youth: 1990-2021 and projections to 2045.","authors":"Kexin Zhang, Chengxia Kan, Fang Han, Yanhui Ma, Yuqun Wang, Xuan Li, Guoji Xiong, Jinyan Chen, Xiao Yu, Ningning Hou, Xiaodong Sun","doi":"10.1007/s12020-025-04356-y","DOIUrl":"https://doi.org/10.1007/s12020-025-04356-y","url":null,"abstract":"<p><strong>Aims: </strong>This study examines the global burden of type 1 diabetes (T1D) among adolescents and young adults (15-39 years) from 1990-2021, with projections to 2045.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease (GBD) 2021, we analyzed T1D prevalence, incidence, deaths, disability-adjusted life years (DALYs), and annual percent change (AAPC), with regional and gender differences.</p><p><strong>Results: </strong>In 2021, global T1D prevalence among 15-39-year-olds was 7.34 million cases (95% UI: 5.94-9.00 million), with males accounting for 50.66%. Incidence was 196,104 cases (141,606-277,782), with 55.31% males. From 1990-2021, prevalence increased from 200.11-246.89 per 100,000 (AAPC 0.68), and incidence rose from 5.10-6.59 per 100,000 (AAPC 0.83). In 2021, there were 16,135 deaths and 1.40 million DALYs, with 54.94% attributed to males. Death rates decreased (AAPC -0.35). Middle SDI regions had the highest prevalence (1.86 million) and incidence (54,541), while high SDI areas had the highest rates. Low-middle SDI areas had the most deaths (5170) and DALYs (419,772). South Asia had the highest prevalence (1.73 million), incidence (46,310), deaths (5189), and DALYs (413,293). India, the USA, and China had the highest prevalence and incidence, while Finland, Canada, and Italy had the highest rates. By 2045, T1D incidence is projected to reach 571,556 cases, predominantly affecting those aged 15-19 years.</p><p><strong>Conclusion: </strong>The rising burden of T1D among adolescents and young adults underscores the need for targeted interventions and healthcare policies, particularly in high-risk regions.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining gender, BMI, and lifestyle factors as indicators of type 2 diabetes risk in the Ukrainian population.","authors":"Jeongwon Richter, Johanna Buchcik, Adekunle Adedeji","doi":"10.1007/s12020-025-04353-1","DOIUrl":"https://doi.org/10.1007/s12020-025-04353-1","url":null,"abstract":"<p><strong>Purpose: </strong>Despite significant advances in diabetes understanding and management, it remains a major global public health challenge. This study examines the influence of gender, body mass index (BMI), and lifestyle factors on developing type 2 diabetes (T2D) in the Ukrainian population. By exploring these key risk factors, the study aims to enhance understanding of T2D determinants and contribute to targeted prevention strategies in Ukraine.</p><p><strong>Methods: </strong>This current analysis uses cross-sectional secondary data from 12,092 individuals who visited medical mobile teams (MMTs) in four Ukrainian regions (Lviv, Rivne, Dnipro, and Poltava) between April 6 and August 8, 2023. Multiple logistic regression was employed to explore various risk factors associated with T2D.</p><p><strong>Results: </strong>The results suggest that overweight individuals were 3.02 times more likely to have T2D (Wald (1) = 233.10, p < 0.001, 95% CI: 2.62-3.48), while each unit increase in BMI raised the likelihood by 1.05-fold (Wald (1) = 56.26, p < 0.001). An unhealthy diet increased the risk by 1.29 times (Wald (1) = 13.99, p < 0.001). Women had 1.16 times higher T2D prevalence than men (Wald (1) = 3.93, p <0.05). Sedentary individuals were 16.1% less likely to have T2D (Wald (1) = 8.69, p < 0.01).</p><p><strong>Conclusion: </strong>This study is significant in that self-perceived overweight status was found to be the most important risk factor associated with T2D prevalence. This provides important guidance for organisations seeking to support T2D diagnosis and management efforts in Ukraine and emphasises the need to recognise self-perceived overweight status as an important consideration.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of autoimmune comorbidities and association with glycemic control by CGM-derived parameters in type 1 diabetes.","authors":"Ana Margarida Lopes, Ana Rita Leite, Patrícia Ferreira, Inês Meira, João Menino, Mariana Lourenço, Joana Lagoa, Beatriz Viveiros, Maria João Barbosa, Sílvia Santos Monteiro, Joana Queirós, João Sérgio Neves, Celestino Neves","doi":"10.1007/s12020-025-04354-0","DOIUrl":"https://doi.org/10.1007/s12020-025-04354-0","url":null,"abstract":"<p><strong>Purpose: </strong>Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease frequently associated with other autoimmune diseases. This study aims to evaluate the prevalence of additional autoimmunity in adults with T1D and its association with glycemic control, chronic complications, and other comorbidities.</p><p><strong>Methods: </strong>We performed a cross-sectional study in adult patients with T1D, followed at the Endocrinology Department of a tertiary hospital, between May 2022 and May 2024. Clinical data collected included glycemic control (HbA1c and continuous glucose monitoring [CGM] parameters), diabetes complications, and other comorbidities. These parameters were compared according to the history of autoimmune diseases. Statistical analysis was performed using parametric and non-parametric tests, ANCOVA and logistic regression models, unadjusted and adjusted for age and sex.</p><p><strong>Results: </strong>Of the 439 participants (48.8% female and mean age 36.8 ± 14.1 years), 33.8% had at least one autoimmune disease, predominantly Hashimoto's thyroiditis (28.8%) and celiac disease (3.9%), with higher prevalence in women (p < 0.001). HbA1c (7.7 ± 1.3 vs. 7.8 ± 1.4%, p = 0.53) and CGM-derived parameters, such as glucose management indicator (7.4 ± 0.9 vs. 7.4 ± 0.8%, p = 0.44) and time in range (58.7 ± 18.9 vs. 56.6 ± 16.5%, p = 0.84), were similar in patients with and without autoimmune diseases.</p><p><strong>Conclusions: </strong>Over one fourth of patients with T1D had a concomitant autoimmune disease. Our results suggest that the presence of other autoimmune diseases may not preclude the attainment of similar glycemic targets. Given the high risk of autoimmunity in T1D, systematic screening and personalized treatment should be considered. Prospective studies are warranted to explore the long-term implications on metabolic control and cardiovascular outcomes.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}